EXHIBIT 99.2
GENENTECH, INC. | |||||||
Three Months | |||||||
2005 | 2004 | ||||||
Revenues: | |||||||
Product sales | $ | 1,450,979 | $ | 1,005,511 | |||
Royalties | 237,777 | 153,942 | |||||
Contract revenue | 63,066 | 43,191 | |||||
Total operating revenues | 1,751,822 | 1,202,644 | |||||
Costs and expenses: | |||||||
Cost of sales | 230,127 | 165,990 | |||||
Research and development | 328,850 | 234,086 | |||||
Marketing, general and administrative | 349,323 | 264,648 | |||||
Collaboration profit sharing | 219,591 | 151,894 | |||||
Recurring charges related to redemption | 27,191 | 34,534 | |||||
Special items: litigation-related | 13,507 | 13,419 | |||||
Total costs and expenses | 1,168,589 | 864,571 | |||||
Operating margin | 583,233 | 338,073 | |||||
Other income, net(1) | 22,391 | 23,510 | |||||
Income before taxes | 605,624 | 361,583 | |||||
Income tax provision | 246,211 | 130,709 | |||||
Net income | $ | 359,413 | $ | 230,874 | |||
Earnings per share: | |||||||
Basic | $ | 0.34 | $ | 0.22 | |||
Diluted | $ | 0.33 | $ | 0.21 | |||
Weighted average shares used to compute earnings per share: | |||||||
Basic | 1,060,539 | 1,055,140 | |||||
Diluted | 1,086,964 | 1,077,093 | |||||
___________________
(1) | "Other income, net" includes interest income, interest expense, net realized gains from the sale of certain biotechnology equity securities and write-downs for other-than-temporary impairments in the fair value of certain biotechnology debt and equity securities. For further detail, refer to our web site at www.gene.com. |
- 1 -
GENENTECH, INC. | |||||||
Nine Months | |||||||
2005 | 2004 | ||||||
Revenues: | |||||||
Product sales | $ | 3,911,095 | $ | 2,682,577 | |||
Royalties | 670,014 | 459,899 | |||||
Contract revenue | 159,170 | 163,381 | |||||
Total operating revenues | 4,740,279 | 3,305,857 | |||||
Costs and expenses: | |||||||
Cost of sales | 750,649 | 467,153 | |||||
Research and development | 850,215 | 637,317 | |||||
Marketing, general and administrative | 1,021,174 | 788,616 | |||||
Collaboration profit sharing | 594,666 | 423,546 | |||||
Recurring charges related to redemption | 96,155 | 110,952 | |||||
Special items: litigation-related | 44,291 | 40,276 | |||||
Total costs and expenses | 3,357,150 | 2,467,860 | |||||
Operating margin | 1,383,129 | 837,997 | |||||
Other income, net(1) | 70,290 | 61,274 | |||||
Income before taxes | 1,453,419 | 899,271 | |||||
Income tax provision | 513,666 | 321,040 | |||||
Net income | $ | 939,753 | $ | 578,231 | |||
Earnings per share: | |||||||
Basic | $ | 0.89 | $ | 0.55 | |||
Diluted | $ | 0.87 | $ | 0.53 | |||
Weighted average shares used to compute earnings per share: | |||||||
Basic | 1,055,028 | 1,057,006 | |||||
Diluted | 1,080,921 | 1,082,081 | |||||
___________________
(1) | "Other income, net" includes interest income, interest expense, net realized gains from the sale of certain biotechnology equity securities and write-downs for other-than-temporary impairments in the fair value of certain biotechnology debt and equity securities. For further detail, refer to our web site at www.gene.com. |
- 2 -
GENENTECH, INC. | ||||||
September 30, | ||||||
2005 | 2004 | |||||
Selected balance sheet data: | ||||||
Cash, cash equivalents and short-term investments | $ | 2,905,543 | $ | 1,760,164 | ||
Accounts receivable - product sales, net | 509,465 | 548,555 | ||||
Accounts receivable - royalties, net | 264,179 | 193,650 | ||||
Accounts receivable - other, net | 189,341 | 143,622 | ||||
Inventories | 621,389 | 559,920 | ||||
Long-term marketable debt and equity securities | 1,242,866 | 1,310,422 | ||||
Property, plant and equipment, net | 3,128,089 | 1,922,313 | ||||
Goodwill | 1,315,019 | 1,315,019 | ||||
Other intangible assets | 587,911 | 677,049 | ||||
Long-term assets | 1,030,842 | 774,435 | ||||
Total assets | 12,099,306 | 9,408,360 | ||||
Total current liabilities | 1,354,938 | 1,106,656 | ||||
Total liabilities | 4,376,048 | 2,441,064 | ||||
Total stockholders' equity | 7,723,258 | 6,967,566 | ||||
Year-to-date: | ||||||
Capital expenditures | $ | 1,106,930 | $ | 418,214 | ||
Total depreciation and amortization expense | 275,632 | 259,583 |
- 3 -
GENENTECH, INC. | ||||||
Three Months | ||||||
2005 | 2004 | |||||
Net U.S. Product Sales | ||||||
Rituxan | $ | 456,227 | $ | 393,000 | ||
Herceptin | 215,148 | 126,300 | ||||
Avastin | 325,156 | 183,003 | ||||
Growth Hormone | 88,585 | 84,931 | ||||
Thrombolytics | 57,903 | 52,867 | ||||
Pulmozyme | 46,593 | 39,816 | ||||
Xolair | 81,550 | 53,856 | ||||
Raptiva | 20,887 | 16,265 | ||||
Tarceva | 73,222 | - | ||||
Total U.S. product sales | 1,365,271 | 950,038 | ||||
Net product sales to collaborators | 85,708 | 55,473 | ||||
Total Product Sales | $ | 1,450,979 | $ | 1,005,511 | ||
Nine Months | ||||||
2005 | 2004 | |||||
Net U.S. Product Sales | ||||||
Rituxan | $ | 1,347,125 | $ | 1,144,813 | ||
Herceptin | 497,205 | 352,996 | ||||
Avastin | 773,695 | 354,134 | ||||
Growth Hormone | 275,570 | 256,896 | ||||
Thrombolytics | 160,105 | 147,133 | ||||
Pulmozyme | 137,482 | 114,340 | ||||
Xolair | 227,183 | 127,332 | ||||
Raptiva | 58,803 | 35,971 | ||||
Tarceva | 190,993 | - | ||||
Total U.S. product sales | 3,668,161 | 2,533,615 | ||||
Net product sales to collaborators | 242,934 | 148,962 | ||||
Total Product Sales | $ | 3,911,095 | $ | 2,682,577 | ||
- 4 -